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ABSTRACT  
A novel stability indicating RP- HPLC method was developed for the estimation of Apremilast in bulk and marketed formulation. Separation was 
achieved by using Shimadzu HPLC Analytical Technologies Limited C18 (250 mm x 4.6 mm, 5µm) as stationary phase. The optimized mobile 
phase consist of potassium dihydrogen ortho phosphate (pH-3.2): acetonitrile in ratio of 40:60 %v/v with flow rate of 1mL/min by using methanol 
as diluent. Retention time of Apremilast was found to be 5.4 min which was estimated at wavelength 360nm. Linearity of Apremilast was 
observed in the concentration range of 50-400µg/mL with r² value of 0.9999. Assay of Apremilast tablet was found to be 99.14-100.75%. Stability 
indicating nature of RP- HPLC method was estimated by conducting degradation kinetic study. The forced degradation of Apremilast bulk 
indicate that degradation in acidic, alkali, oxidative and photolysis condition were found to be 21%, 6.5%, 25.7% and 3.9% respectively. The 
kinetic study of apremilast in alkali degradation followed first order kinetic study. The result indicate that the developed RP-HPLC method is 
suitable for estimation of Apremilast in presence of degradant product. The above method was validated as per ICH guideline. 
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Abbreviation: 
APR             : Apremilast 
ICH              : International Conference of Harmonization  
RP-HPLC   : High-performance liquid chromatography 
%RSD        : Relative standard deviation 
INTRODUCTION: 
Apremilast is a phosphodiesterase 4 (PDE4) inhibitor, which 
mediates the activity of cyclic adenosine monophosphate 
(cAMP), a secondary messenger. The chemical name of APR 
is N- 2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2- (methyl 
sulfonyl) ethyl]-1, 3-dioxo-2, 3-dihydro- 1H-isoindol -4-yl 
acetamide. Apremilast is indicated for the treatment of 
active psoriatic arthritis in adults, for the treatment of active 
moderate to severe psoriatic arthritis [1]. In July 2019, 
apremilast was granted a new FDA approval for the 
treatment of oral ulcers associated with Behcet's disease, an 
autoimmune condition that causes recurrent skin, blood 
vessel, and central nervous system inflammation [2]. This 
method aimed to validate the developed RP- HPLC method 
for determination of apremilast drug as per the ICH 
guideline. There are many Analytical method like U.V 
Spectrophotometric methods[3], HPLC methods[4] and 
Stability indicating RP-HPLC[5] are reported for 
determination of APR but there were no reported stability 
indicating RP-HPLC method along with degradation kinetic 
study for APR. Accordingly it was found that present research 
study has some extra advantages to develop and validate 
Stability indicating method for determination of APR in the 
presence of degradant products and to perform degradation 
kinetic study of APR. 
 
Figure: 1 Chemical structure of APR [6] 
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MATERIALS AND METHODS 
Instrumentation: Shimadzu HPLC system with UV Detector, 
UV Visible spectrometer, pH meter, electronic balance. 
Chromatographic condition: 
Table: 1 Chromatographic Condition 
Parameter Chromatographic conditions 
Instrument Shimadzu LC20A 
Column Analytical Technologies Limited C18 
column(250 mm x 4.mm,5µm) 
Flow rate 1 mL /min 
Detection wavelength 360nm 
Injection volume 20μl 
Run time 10 min 
Temperature Ambient 
Mobile phase potassium dihydrogen 
orthophosphate: Acetonitrile(40:60) 
Diluent 90:10(methanol:DMSO) 
 
Mobile phase preparation: 
Buffer for mobile phase: Phosphate buffer (50mM) prepared 
by dissolving about 6.8g potassium dihydrogen 
orthophosphate (pH-3.2)in 1000 mL double distilled water. 
Mobile phase preparation: Phosphate buffer (pH-3.2): 
acetonitrile mixing in ratio of 40:60%v/v. Before use the 
mobile phase was filtered through 0.45µm Nylon-6, 6 
membrane filter followed by 5min of sonication. 
Preparation of standard Stock solution: The standard 
stock solution of APR was prepared by weighed about 10mg 
APR in 10 ml volumetric flask and dissolving in Diluent and 
make up the mark with diluent. Further, dilute 1mL of 
standard stock solution in 10mL volumetric flask and volume 
was made up to mark with diluent. 
Method Validation: The developed method was validated 
by different parameters like specificity, linearity, precision, 
accuracy, ruggedness, robustness, LOD and LOQ as per ICH 
Q2 (R3) guidelines [7-9, 12] 
Specificity: Specificity is the ability to assess unequivocally 
the analyte in the presence of components which may be 
expected to be present [8]. Typically these might include 
impurities, degradants, matrix etc. Specificity was estimated 
by injecting the APR standard solution, sample solution and 
blank. 
Linearity: The linearity of an analytical procedure is its 
ability (within given range) to obtain test results which are 
directly proportional to the concentration (amount) of 
analyte in the sample. A graph of peak area versus 
concentration was plotted. 
Linearity was prepared at 6 independent levels from 50-
400µg/mL. 
Precision: The precision of an analytical procedure 
expresses the closeness of agreement (degree of scatter) 
between the series of measurements obtained from multiple 
sampling of the same homogeneous sample under the 
prescribed conditions [7] 
 REPEATABILITY: Repeatability expresses the precision 
under the same operating conditions over a short 
interval of time. Repeatability is also termed intra-
assay precision [7]. It was performed at 6 levels of same 
target concentration (300µg/mL) with different 
standard stock solution (500 µg/mL). 
Intermediate precision: (within laboratory variation) 
Different days/Different equipment. 
 INTRADAY PRECISION: Intraday precision can be 
define as within day precision .It was performed at 3 
levels of 3 different concentration (50,100,150 µg/mL) 
of APR within a day from standard stock solution (500 
µg/mL). 
 INTER-DAY PRECISION: Inter-day precision can be 
define as within a day precision. It was performed at 3 
levels of 3 different concentration (50,100,150 µg/mL) 
of APR on different day from same standard stock 
solution (500 µg/mL). 
 
Accuracy: The accuracy of analytical procedure expresses 
the closeness of agreement between the value which is 
accepted either as a conventional true value or an accepted 
reference value and the value found. This is sometimes 
termed trueness [7]. Accuracy of method was performed at 
100µg/mL in triplicate at 80%, 100% and 120% by standard 
addition method. 
LOD: The limit of detection is determine by the individual 
analytical procedure of samples with known concentration 
of drug and by establishing the lowest level of analyte in a 
sample which can be detected, but not necessarily 
quantitated the specific value. 
The Actual lowest concentration of analyte in sample 
detected is compared with blank result and which is based 
on standard deviation of the response and the slope [7]. 
LOD=3.3 σ/S 
Where, S = the slope of calibration curve 
σ = the standard deviation of the response 
LOQ: The limit of quantitation is determined by the individual 
analytical procedure of samples and establishing the lowest 
amount of analyte in a sample, which can be determined 
with appropriate precision and accuracy [7]. 
LOQ=10 σ/S 
Where, S=the standard deviation of response 
σ = Mean of slopes of the calibration curves 
Robustness: The robustness of an analytical procedure is an 
estimation of its capacity to remain unaffected by small, but 
deliberate variations in method parameters. 
• Flow rate 
• Concentration of acetonitrile 
Ruggedness: The ruggedness is an analytical method of the 
degree of reproducibility of samples results obtained by 
analysis of the same samples under a different conditions for 
example in different pH, different temperature and different 
mobile composition [7-8]. 
Degradation Study: Degradation study was carried out in 
acidic, alkali, oxidative condition. The standard Stock 
solution for forced degradation study 1000µg/mL of APR 
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was prepared. Kinetic study of Apremilast was performed to 
determine the order of degradation kinetic under different 
stress condition [11]. 
Acidic Degradation: 
From the standard stock solution 3mL was taken in a 10-mL 
volumetric flask. Further 0.5mL of 0.05N HCl was added in 
the flask. The mixture was kept at room temperature for 20 
min. Solution was neutralized with 0.5 mL of 0.05N NaOH 
and the volume was made up to mark with diluent to achieve 
the concentration of 300µg/ mL. Solution was then filtered 
with 0.45-µm Nylon syringe filter and injected in the system. 
Alkaline Degradation: 
From the standard stock solution 3mL was taken in a 10-mL 
volumetric flask. Further 0.5mL of 0.05N NaOH was added in 
the flask. The mixture was kept at room temperature for 20 
min. Solution was neutralized with 0.5 mL of 0.05N HCl and 
the volume was made up to the mark with diluent to achieve 
the concentration of 300µg/ mL. Solution was then filtered 
with 0.45- 
µm Nylon syringe filter and injected in the system. 
Oxidative Degradation: 
From the standard stock solution 3mL was taken in a 10-mL 
volumetric flask. Further 1mL of 0.2% Hydrogen peroxide 
was added in the flask and the volume was made up to the 
mark with diluent to achieve the concentration of 300µg/ 
mL. Solution was then filtered with 0.45-µm Nylon syringe 
filter and injected in the system. 
 
Photolytic Degradation: 
Photolytic degradation about 10 mg of bulk drug was weighed 
and added in the Petri dish. Petri dish exposed to 5382 LUX 
and 144UW/cm2 for 10 days. Degradation samples were 
subjected to analysis after suitable dilutions with diluent 
Degradation Kinetics Study: 
The Degradation kinetic study was done in alkaline 
condition. The conditions selected for the kinetic study was 
0.05 N and 0.1N of NaOH at 30ºC and 50°C .Then 0.5 mL 
Stock solution in 10 mL volumetric flask and 2 mL of 0.05N 
and 0.1N NaOH was further added to the flask. The solution 
was subjected to two different conditions at 30°C and 
50ºC.The solution was neutralized with 0.5 mL of 0.05N and 
0.1N HCl respectively and made up to mark with diluent and 
make the concentration 300 µg/mL. Solution was filtered 
with 0.45-µm Nylon syringe filter and injected in the system. 
Percentage degradation of APR was estimated at above 
mentioned conditions. 
RESULT AND DISCUSSION: 
Specificity: 
The specificity of the analytical method of APR is established 
by injecting the sample solution into the HPLC System. 
• Diluent solution is used as blank (methanol) 
• Standard solution of APR(100µg /mL) 
• Test solution(APR marketed formulation) 
The specificity data of APR mention in table 2.
 
 
Figure.2 Chromatogram of blank methanol 
Figure.3 
Chromatograph of standard APR 
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Figure.4 chromatograph of Test solution APR Table: 2 Specificity data of APR 
 Sr. no. Sample Name  Drug Name Specificity 
       1 Blank No Peak - 
       2  Standard APR Specific 
       3 Test APR Specific 
 
 
System Suitability: 
The prepared 100µg/mL standard solution of APR was 
measured for parameters like retention time (RT), 
Theoretical plate and Tailing Factor by injecting the solution 
at three replicate level. Below mentioned values are within 
acceptable limit of chromatographic condition. The system 
suitability data of APR mention in table3. 
Table: 3 System Suitability data of APR 
Parameters Mean(n=3) %RSD 
RT(min) 5.41 1.51 
Theoretical plate 4958.67 1.68 
Tailing factor 1.306 0.93 
 
Linearity: 
The calibration curve of APR is linear in the concentration 
range of 50-400µg/mL. The regression data analysis of RP-
HPLC method is mention in table 4. 
Table: 4 linearity data of APR 
      Concentration (µg/mL) Area(mv) 
Mean(n=6) 
%RSD 
50 393.844 0.45 
100 806.067 0.69 
200 1633.766 0.47 
300 2408.507 0.33 
400 3207.949 0.42 
 
 
 
Figure: 5 chromatograph of APR Linearity Conc. (µg/mL) 
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Figure: 6 Calibration curve of APR Table: 5 Regression data analysis RP-HPLC 
Parameter APR 
Wavelength 360nm 
Range 50-400µg/mL 
Regression Equation Y=8.0275x+4.2493 
Slop(m) 8.0275 
Intercept(c) 4.249 
Correlation coefficient 0.9999 
 
 
Precision: 
Precision of analytical method was estimated by 
Repeatability, intraday precision and inter day precision of 
the APR standard solution. The Repeatability %RSD was 
0.77 and intraday precision %RSD was 0.92 and that of inter 
day precision was 1.25. The results of repeatability data, 
intraday and interday precision data of APR are shown in 
table 6, table 7 and table 8 respectively. 
Table: 6 Repeatability data of APR 
Repeatability( 100μg/mL) 
Replicates Area 
1 804.56 
2 796.31 
3 810.72 
4 802.2 
5 794.32 
6 806.3 
mean 802 
%RSD 0.77 
 
Table: 7 Intraday Precision data of APR 
Concentration(µg/mL) Average area (n=3) %RSD 
50 394.74 0.49 
100 803.77 0.92 
300 2433.62 0.42 
 
Table: 8 Interday Precision data of APR 
Concentration(µg/mL) Average area (n=3) %RSD 
50 394.04 0.83 
100 801.39 1.25 
300 2479.05 1.20 
 
Accuracy: 
Accuracy was calculated by performing the recovery study. A 
standard known quantity of APR was added into aliquots of 
sample solutions at the three different levels in 80%, 100%, 
120% and then diluted with the solvent. The percentage 
recovery obtained in range 99.71%, 99.48%, and 99.86% 
respectively as mention in table 9. 
Linearity of APR 
4000.000 
3000.000 
2000.000 
1000.000 
0.000 
y = 8.0275x + 4.2493 
R² = 0.9999 
0 100 200 300 400 500 
Concentration(μg/mL) 
A
re
a 
Patel et al                                                                                                                     Journal of Drug Delivery & Therapeutics. 2020; 10(2):76-85 
ISSN: 2250-1177                                                                                  [81]                                                                                 CODEN (USA): JDDTAO 
Table: 9 Accuracy data of APR (n=3) 
Spiked 
level 
Conc present in 
mixture(μg/mL) 
Conc added 
(μg/mL) 
Conc recovered 
((μg/mL) 
%Recovery 
±SD 
80% 100 80 179.54  
99.71±0.37 80% 100 80 178.79 
80% 100 80 180.13 
100% 100 100 200.08  
99.48±0.51 100% 100 100 198.72 
100% 100 100 198.09 
120% 100 120 221.13  
99.86±0.59 120% 100 120 219.26 
120% 100 120 218.64 
 
 
Limit of Detection and Limit of Quantification: 
Limit of Detection was 0.04 and the Limit of Quantification 
was 0.13 was calculated. 
Robustness: 
The developed method was found to be robust when changes 
were made in parameters as mentioned in table like change in 
mobile phase, change in flow rate, and change in pH. Average 
peak area and %RSD was noted. The Robustness data of APR 
mention in table 10. 
Assay of Marketed formulation: 
The assay was estimated by taking twenty tablets of APR 
weighted and crushed. The solution was prepared by 
weighed 10mg APR in 10mL volumetric flask and making 
volume up to the mark with diluent. From stock solution take 
1mL in 10mL volumetric flask and making volume up to 
mark with diluent. The Assay result of APR mention in table 
11.
 
Table: 10 Robustness data of APR (n=3) 
Factor Level of change Average peak 
Area 
%RSD 
 
Mobile phase 
KH2PO4:ACN=58:42 779.7 0.72 
KH2PO4:ACN=60:40 777.9 0.46 
KH2PO4:ACN=56:44 778.3 0.52 
 
Flow rate 
0.8 776.2 0.51 
1 777.9 0.46 
1.2 777.7 0.45 
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Table: 11 Assay data of APR 
Sr.No %Drug Recovered (n=6) Mean % Drug Recovered %RSD of Drug 
Recovered 
1 99.14  
 
 
99.78 
 
 
 
0.68 
2 100.20 
3 99.90 
4 100.75 
5 99.91 
6 99.84 
 
Degradation Study: The degradation was observed in acidic condition (21%) and in alkaline condition (6.5%), in 0.2% v/v 
Hydrogen peroxide condition (25.7%) and in photolysis degradation (3.9). Degradation behaviour in different condition 
mention in table 12.  
 
 
Figure: 7 Alkaline Degradation of APR 
 
Figure: 8 Acidic Degradation of APR 
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Figure: 9 oxidative Degradation of APR 
 
Figure: 10 Photolytic degradation Table: 12 Stability studies of APR 
Degradation 
Type 
Stress 
condition 
Time %Assay % of Degradation 
Product 
Control sample As Such - 100 - 
Acidic 
degradation 
0.05M MeoH 
HCl 
20min 79 21 
Alkaline 
degradation 
0.05M MeoH 
NaOH 
20min 93.5 6.5 
Oxidative 
degradation 
0.2% H2O2 20min 74.3 25.7 
Photolysis 
degradation 
5382 LUX and 
144UW/cm2 
10 days 96.1 3.9 
 
Degradation kinetic study: 
Degradation kinetic study of bulk drug in alkaline condition 
at 30ºC and 50ºC that result show that the decrease in area 
with increasing the time. The plots of zero order (%drug 
remaining vs time), first order (log c value vs time) and 
second order (1/log c vs time) were plotted individually. 
From the result obtain it was concluded that the r2 value of 
first order appeared high as compared to the r2 value of zero 
order and second order. So, alkali degradation of APR 
followed first order kinetic. The result of alkaline 
degradation kinetic study of APR mention in table 13.
 
 
 
 
 
 
 
 
 
Figure: 11 Log C vs Time Graph for alkaline condition in 0.05N NaOH at 30ºC (a) and 50ºC (b) 
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Figure: 12 Log C vs Time Graph for alkaline condition in 0.1N NaOH at 30ºC (a) and 50ºC (b) Table: 13 Degradation Kinetic 
study of APR in alkaline condition 
Table: 13 Degradation Kinetic study of APR in alkaline condition 
As such 
Area 
2385.286 Degradation kinetic study 
Target 
conc(μg/mL) 
300 
Degradation 
condition 
Temperature Time(min) %Assay Degradation rate 
constant k 
t ½(min) 
 
 
 
 
 
0.05N 
NaOH 
 
 
30°C 
0 77.15 0.000 0.00 
10 62.84 0.004 180.31 
20 47.82 0.009 75.36 
30 41.11 0.012 56.38 
60 28.96 0.020 34.93 
 
 
 
50°C 
0 77.15 0.000 0.00 
10 57.43 0.006 124.26 
20 37.35 0.014 48.45 
30 28.11 0.021 33.77 
60 17.23 0.032 21.51 
 
 
 
 
0.1N NaOH 
 
 
30°C 
0 71.05 0.000 0.00 
10 50.17 0.007 103.22 
20 30.61 0.017 40.55 
30 21.42 0.023 30.11 
60 14.13 0.036 19.33 
 
 
50°C 
0 71.05 0.000 0.00 
10 47.41 0.008 88.32 
20 25.60 0.021 32.81 
30 16.76 0.031 22.07 
60 10.52 0.044 15.73 
 
 
CONCLUSION: 
The developed RP-HPLC method is simple, specific, accurate, 
precise and stability indicating which can be useful in routine 
analysis laboratories for the determination of APR in bulk 
drug and pharmaceutical formulation without any 
interference from excipient, impurity and degradation 
product. This method have been validated as per ICH 
guidelines, and it meets all the acceptance criteria given in 
ICH guidelines. Degradation kinetic study shows that APR 
follows first order kinetic in alkaline condition. 
REFERENCES: 
1. “FDA LABEL of apremilast” 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017
/205437s006lbl.pdf 
2. Schafer P. Apremilast mechanism of action and application to 
psoriasis and psoriatic arthritis. Biochemical pharmacology. 
2012 Jun 15; 83(12):1583-90. 
3. Xiong K, Ma X, Cao N, Liu L, Sun L, Zou Q, Wei P. Identification, 
characterization and HPLC quantification of impurities in 
apremilast. Analytical Methods. 2016;8(8):1889-97. 
4. Landge SB, Dahale SB, Jadhav SA, Solanki PV, Bembalkar SR, 
Mathad VT. Development and validation of stability indicating 
rapid RP-LC method for determination of process and 
degradation related impurities of Apremilast, an anti-
inflammatory drug. Am J Anal Chem. 2017 Jun 12; 8:380. 
5. https://www.researchgate.net/figure/Chemical-structure-of-
apremilast_fig1_331389543 
6. Chaudhari SR, Shirkhedkar AA. Design of Experiment Avenue 
for development and validation of RP-HPLC-PDA method for 
Patel et al                                                                                                                     Journal of Drug Delivery & Therapeutics. 2020; 10(2):76-85 
ISSN: 2250-1177                                                                                  [85]                                                                                 CODEN (USA): JDDTAO 
determination of apremilast in bulk and in in-house tablet 
formulation. Journal of Analytical Science and Technology. 
2019 Dec; 10(1):10. 8.https://www.gmp-
compliance.org/guidelines/gmp-guideline/ich-q2r1-
validation-of- analytical-procedures-text-and-methodology 
7. Lonkar N, Sawant S, Dole M. Development and validation of 
stability indicating RP-HPLC method for the estimation of 
apremilast by forced degradation studies. W. J Pharm Pharm 
Sci. 2017a. 2017; 6:1493-502 
8. Badhe P, Aher S, Saudagar RB. Analytical Method of 
Apremilast: A Review. Journal of Drug Delivery and 
Therapeutics. 2019 Jun 29; 9(3-s):1116-9. 
9. Bhole RP, Naksakhare SR, Bonde CG. A Stability Indicating 
HPTLC Method for Apremilast and Identification of 
degradation products using MS/MS. Journal of Pharmaceutical 
Sciences and Research. 2019 May 1; 11(5):1861-9. 
10. Ravisankar P, Sulthana MS, Babu PS. Development and 
validation of stability-indicating UV spectrophotometric 
method for determination of Apremilast in bulk and 
pharmaceutical dosage form. Ind J Res Pharm Biotechnol. 
2017; 5:47. 
14.https://www.ema.europa.eu/en/documents/scientific-
guideline/ich-q-2-r1-validation- analytical-procedures-text-
methodology-step-5_en.pdf 
11. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson 
RT, Hu C, Day RM. Efficacy of apremilast in the treatment of 
moderate to severe psoriasis: a randomised controlled trial. 
The Lancet. 2012 Aug 25; 380(9843):738-46. 
12. Pandya CP, Rajput SJ. Stress Degradation Studies of Anagliptin, 
Development of Validated Stability Indicating Method, 
Degradation Kinetics Study, Identification and Isolation of 
Degradation Products. Chromatographia. 2018 Nov 1; 
81(11):1533-50. 
13. Pandya CP, Rajput SJ. Stress Degradation Studies of Riociguat, 
Development of Validated Stability Indicating Method, 
Identification, Isolation and Characterization of Degradation 
Products by LC-HR-MS/MS and NMR Studies. Indian Journal 
Of Pharmaceutical Education And Research. 2019 Oct 1; 
53(4):S630-41. 
14. Bockhorn H, Hornung A, Hornung U, Schawaller D. Kinetic 
study on the thermal degradation of polypropylene and 
polyethylene. Journal of Analytical and Applied Pyrolysis. 
1999 Jan 1; 48(2):93-109. 
15. SHRIMALI C, BAGHEL M, RAJPUT S. Development and 
validation of stability indicating rp-hplc method of nepafenac 
and its degradation products: application to degradation 
kinetic. Int J Pharm Pharm Sci. 2014; 6(9):387-93. 
 
